Cardiovascular

Eptifibatide as Effective as Abciximab in Primary PCI for Acute ST Elevation Myocardial Infarction: EVA-AMI Study

November 6, 2007
Uwe Zeymer
Uwe Zeymer
REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
UWE ZEYMER, Herzzentrum Ludwigshafen, Germany
The glycoprotein 2B 3A antagonist eptifibatide has performed as well as standard abciximab therapy in patients receiving primary angioplasty for acute myocardial infarction. So according to Uwe Zeymer who presented findings on this it can be used in this setting just as it is already being used in elective PCI. Sarah Maxwell interviewed Dr Zeymer at the Orlando conference.

Download this interview

Add podcast to iTunes

Similar Interviews

  • Audio Journal of Cardiovascular Medicine: Reduced Mortality and Repeat MI with Enoxaparin for Patients with ST Elevation Myocardial Infarction

    • HARVEY WHITE, Auckland City Hospital, New Zealand REFERENCE: European Heart Journal Advanced On-Line Publication April 24th, 2007 Enoxaparin could be the new

  • Audio Journal of Cardiovascular Medicine 12.1, January 2006

    • Reporting from: American Heart Association Annual Scientific Sessions November 13-16, 2005, Dallas In this edition: Bryan Williams told American Heart Association attendees that

  • Lytic Therapy Does Not Facilitate PCI

    • Frans Van de Werf, University of Leuven Abstract Lancet 367:569-578 Results from a new study just published in the Lancet look into

    Post a comment